1 secondary hyperparathyroidism (shpt): assessing the educational support requirements for nurses...
TRANSCRIPT
1
Secondary hyperparathyroidism (SHPT): Assessing the educational support requirements for nurses across EuropeA joint EDTNA/ERCA & Amgen (Europe) GmbH Project
Andrey Gurevich, MD PhDEuropean Development Medical DirectorAmgen (Europe) GmbH
MN-IHQ-AMG-355-2013-July-NP
2
Who is Amgen?
Neupogen®
launched
Expansion toEurope
Expansion to new therapeuticareas (bone)
1990s Tomorrow
Ultra rapid DNAsequencing
InduciblePluripotentstem cells
Gene therapy
Personalized medicines
2000-Today
Strong growth inproduct portfolio
Acquisitions
Global expansion
New modalities
CV and Neuroscience research efforts
1980
Amgen
established
Gene for erythropoietin cloned
1983
First major therapy, EPOGEN®, approved by FDA
1989
3
SHPT as a complication ofchronic kidney disease (CKD)
● Adding to the burden of CKD, is the development of SHPT ● A common complication manifested due to elevated
parathyroid hormone (PTH) levels, as well as calcium and phosphate disturbances
● A vicious cycle of decreased renal function, vitamin D deficiency and impaired mineral metabolism
● SHPT arises in most patients during the progressionof CKD
● Associated manifestations include: renal osteodystrophy, extraskeletal calcification and CVD disease, resulting in increased mortality
● The aim of treatment in secondary hyperparathyroidism isto manage levels of phosphate, PTH and calcium, and in turn reduce the associated clinically important complications
Melanie S et al. J Manag Care Pharm 2007; 13(5): 397-411.
4
The key role of nurses in managing patients with SHPT
Nurses provide care that meets a wide variety of
physical, social and psychological needs for their
CKD and SHPT patients
Patients feed back to nurses on their physical and social
condition
Education and support
5
Determining what educational support is needed
● The EDTNA/ERCA is developing a Nephrology Nurse Education Survey,in association with Amgen (Europe) GmbH, via an unrestricted grant
● The survey aims to understand the professional educational needs of the nephrology nurse in the management of SHPT
● The results will help to provide recommendations on how to improve the focus and quality of education given to nurses in this area
● Activities, such as an advisory board, have already been undertaken to enhance understanding in this area
6
Survey overview
● Selected centres across Europe, starting in Autumn 2013
● Strictly confidential and non-promotional online survey covering the following topics:
Background and nephrology experience
General knowledge of SHPT
Laboratory values and reaching targets
Therapies and adherence
Patient management and side effects
General training and education
7
A sample question
How often do you typically ask your patients about side effects that might be associated with their secondary hyperparathyroidism therapy?
A. AnnuallyB. About once every 3-12 monthsC. About once every 1-2 monthsD. Every monthE. Every visit
8
A sample question
What, in your experience, do you find to be the most challenging aspect of Secondary Hyperparathyroidism management? Select all that apply
• Explaining the disease and treatment to the patient at the point of diagnosis• Patient counselling and on-going support• Conducting regular testing, deciding upon regularity and nature of tests
required for each patient (either alone or with a consultant physician) … etc …
• Other
9
A sample question
What format of educational support would you find most valuable in helping you to support patients with Secondary Hyperparathyroidism? Select all that apply
• Educational training meetings • Online educational training meetings• Distance learning materials (hard copy packs)• Online interactive distance learning modules • Practical toolkits
… etc…• Newsletter and case study series written by nurses and experts
10
The results
Results of the survey will be published and used as a springboard for future educational
themes, materials and learning goals!
11
Thank you!